Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

AVIR

Atea Pharmaceuticals Inc

May 17 • 01:27PM ET

3.69

Dollar change -0.01
Percentage change -0.14	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN IBB SCHA VTWO VHT PRFZ IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.96	Insider Own	12.22%	Shs Outstand	83.44M	Perf Week	-5.01%
Market Cap	311.19M	Forward P/E	-	EPS next Y	-2.45	Insider Trans	-1.22%	Shs Float	73.93M	Perf Month	-0.14%
Income	-163.66M	PEG	-	EPS next Q	-0.66	Inst Own	63.27%	Short Float	2.43%	Perf Quarter	-10.32%
Sales	0.00M	P/S	-	EPS this Y	-63.13%	Inst Trans	-0.16%	Short Ratio	5.67	Perf Half Y	25.25%
Book/sh	5.99	P/B	0.62	EPS next Y	7.87%	ROA	-27.48%	Short Interest	1.80M	Perf Year	-2.25%
Cash/sh	6.43	P/C	0.57	EPS next 5Y	-	ROE	-29.16%	52W Range	2.77 - 5.19	Perf YTD	21.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-71.56%	ROI	-32.36%	52W High	-28.81%	Beta	0.20
Dividend TTM	-	Quick Ratio	13.28	Sales past 5Y	104.50%	Gross Margin	-	52W Low	33.63%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	13.28	EPS Y/Y TTM	-49.18%	Oper. Margin	0.00%	RSI (14)	41.29	Volatility	4.59% 3.18%
Employees	75	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	3.50	Target Price	3.50
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-76.88%	Payout	-	Rel Volume	0.65	Prev Close	3.70
Sales Surprise	-	EPS Surprise	-43.93%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	317.21K	Price	3.69
SMA20	-3.23%	SMA50	-4.42%	SMA200	5.88%	Trades		Volume	129,754	Change	-0.14%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-10-23	Downgrade	JP Morgan	Neutral → Underweight
Jan-06-22	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$14 → $7
Nov-18-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-20-21	Downgrade	JP Morgan	Overweight → Neutral	$61 → $16
Oct-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$55
Nov-25-20	Initiated	Evercore ISI	Outperform
Nov-24-20	Initiated	William Blair	Outperform	$60
Nov-24-20	Initiated	Morgan Stanley	Overweight	$49
Nov-24-20	Initiated	JP Morgan	Overweight	$45

May-15-24 09:01AM	Atea Pharmaceuticals Inc (AVIR) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ... (GuruFocus.com) -6.31%
May-14-24 04:05PM	Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-07-24 07:00AM	Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024 (GlobeNewswire)
Apr-29-24 07:00AM	Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024 (GlobeNewswire)
Mar-27-24 07:00AM	Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients (GlobeNewswire) +6.10%
10:03AM	Loading…
Feb-29-24 10:03AM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 04:58PM	Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results (GuruFocus.com)
04:05PM	Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-21-24 07:00AM	Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024 (GlobeNewswire)
Jan-10-24 09:30AM	Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study (Zacks)
Jan-08-24 04:05PM	Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19 (GlobeNewswire)
Jan-03-24 07:00AM	Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-13-23 07:00AM	Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 (GlobeNewswire)
Nov-09-23 03:57PM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2023 Earnings Call Transcript (Insider Monkey) -9.12%
05:48AM	Q3 2023 Atea Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
04:05PM	Loading…
Nov-08-23 04:05PM	Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Nov-02-23 07:00AM	Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 (GlobeNewswire)
Nov-01-23 07:00AM	Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023 (GlobeNewswire) -5.23%
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE)
Sep-06-23 07:00AM	Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-09-23 06:58AM	Q2 2023 Atea Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-08-23 04:05PM	Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-23 07:00AM	Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023 (GlobeNewswire)
Jun-15-23 07:00AM	Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination (GlobeNewswire)
Jun-05-23 04:20PM	Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-30-23 07:00AM	Atea Pharmaceuticals Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners Affiliate, Concentra Biosciences (GlobeNewswire) -11.97%
May-26-23 07:02PM	Lordstown Motors and Atea Pharmaceuticals Stock See Action From Activist Investors (Barrons.com)
May-23-23 04:05PM	Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners Affiliate, Concentra Biosciences (GlobeNewswire)
May-10-23 11:53AM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2023 Earnings Call Transcript (Insider Monkey)
10:09AM	Loading…
May-09-23 10:09AM	Q1 2023 Atea Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 04:05PM	Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-01-23 04:05PM	Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023 (GlobeNewswire)
Apr-25-23 07:00AM	Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19 (GlobeNewswire)
Apr-12-23 07:00AM	Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases (GlobeNewswire)
Mar-14-23 07:00AM	New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research (GlobeNewswire) +7.72%
Mar-08-23 07:00AM	New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research (GlobeNewswire)
Mar-02-23 09:20PM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2022 Earnings Call Transcript (Insider Monkey) +5.54%
Feb-28-23 04:05PM	Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Feb-23-23 07:00AM	Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023 (GlobeNewswire)
Feb-21-23 07:00AM	Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023 (GlobeNewswire) -5.41%
Feb-15-23 04:05PM	Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections (GlobeNewswire)
Feb-13-23 08:22AM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is a favorite amongst institutional investors who own 62% (Simply Wall St.)
Feb-07-23 07:00AM	Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-09-23 07:00AM	Atea Pharmaceuticals Highlights Strategic Priorities for 2023 (GlobeNewswire)
Jan-04-23 07:00AM	Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-22 11:10AM	Boston biotech retools Covid drug to make 'next generation of Paxlovid' (American City Business Journals) +5.01%
Nov-29-22 07:00AM	Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19 (GlobeNewswire)
Nov-22-22 07:00AM	Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-19-22 09:46AM	Atea Pharmaceuticals (NASDAQ:AVIR) shareholders have endured a 42% loss from investing in the stock a year ago (Simply Wall St.)
Nov-10-22 12:00PM	Atea Pharmaceuticals, Inc. (AVIR) Moves to Buy: Rationale Behind the Upgrade (Zacks) +7.59%
09:35AM	After Plunging 10.6% in 4 Weeks, Here's Why the Trend Might Reverse for Atea Pharmaceuticals, Inc. (AVIR) (Zacks)
Nov-08-22 04:05PM	Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference (GlobeNewswire) -9.88%
Nov-07-22 04:05PM	Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-04-22 08:36AM	Why Atea Pharmaceuticals (AVIR) Might Surprise This Earnings Season (Zacks)
Nov-03-22 07:00AM	Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting (GlobeNewswire)
Nov-02-22 11:14AM	Novo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates (Zacks)
Oct-31-22 07:00AM	Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on November 7, 2022 (GlobeNewswire)
Oct-18-22 10:58AM	One Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) insider upped their stake by 106% in the previous year (Simply Wall St.)
Sep-27-22 09:53AM	Atea (AVIR) Dengue Candidate Gets Fast Track Designation (Zacks)
Sep-26-22 09:33AM	Atea Pharma's Investigational Dengue Treatment Fast Tracked In US (Benzinga) -5.17%
07:00AM	Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue (GlobeNewswire)
Sep-13-22 09:56AM	Atea Pharmaceuticals To Advance Global Late-Stage COVID-19 Study of Bemnifosbuvir (Benzinga) -10.15%
07:00AM	Atea to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 (GlobeNewswire)
Sep-07-22 07:00AM	Atea Pharmaceuticals Announces Upcoming Investor Events (GlobeNewswire)
Sep-06-22 08:18AM	With 62% ownership of the shares, Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is heavily dominated by institutional owners (Simply Wall St.)
Aug-09-22 06:00AM	Atea Pharmaceuticals, Inc. (AVIR) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-08-22 04:30PM	Edited Transcript of AVIR.OQ earnings conference call or presentation 8-Aug-22 8:30pm GMT (Thomson Reuters StreetEvents)
04:05PM	Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-22 07:00AM	Atea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on August 8, 2022 (GlobeNewswire)
Jul-13-22 12:00PM	Atea Pharmaceuticals, Inc. (AVIR) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Jul-11-22 07:00AM	Atea Pharmaceuticals Participates in the William Blair Biotech Focus Conference (GlobeNewswire)
Jul-07-22 08:45AM	Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? (Simply Wall St.)
Jul-02-22 10:23AM	Use This 1 Genius Trick for Finding Dirt Cheap Biotech Stocks in the Bear Market (Motley Fool)
Jun-12-22 09:37AM	Atea Pharmaceuticals (NASDAQ:AVIR) shareholders have endured a 68% loss from investing in the stock a year ago (Simply Wall St.)
Jun-01-22 07:00AM	Atea Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire) -6.35%
May-25-22 06:20AM	Market Participants Recognise Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Earnings Pushing Shares 28% Higher (Simply Wall St.)
May-11-22 10:28AM	A Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) insider increased their holdings by 106% last year (Simply Wall St.)
May-10-22 07:00PM	Atea Pharmaceuticals, Inc. (AVIR) Q1 2022 Earnings Call Transcript (Motley Fool) +9.94%
06:30AM	Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
May-03-22 04:05PM	Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on May 10, 2022 (GlobeNewswire)
Apr-01-22 05:13AM	Top Biotech Stocks for Q2 2022 (Investopedia)
Mar-30-22 12:48PM	What Kind Of Investors Own Most Of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)? (Simply Wall St.)
Mar-28-22 07:00AM	Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Society of Toxicology 61st Annual Meeting (GlobeNewswire)
Mar-21-22 10:04AM	Atea Pharmaceuticals, Inc. (AVIR) Surges 7.4%: Is This an Indication of Further Gains? (Zacks)
Feb-28-22 10:00PM	Atea Pharmaceuticals, Inc. (AVIR) Q4 2021 Earnings Call Transcript (Motley Fool)
07:19PM	Zoom Reports Slowing Growth, but This Stock Is Monday's Real After-Hours Winner (Motley Fool)
06:40PM	Atea Pharma stock jumps as earnings rise, potential COVID-19 therapy advances (MarketWatch)
04:05PM	Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (GlobeNewswire)
Feb-22-22 07:00AM	Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on February 28, 2022 (GlobeNewswire)
Feb-16-22 02:19PM	8 Biotech Stocks So Cheap That Their Technology Is Effectively Free (Barrons.com)
Feb-14-22 09:31AM	10 New Stock Picks of Billionaire Rob Citrone (Insider Monkey) -8.46%
Feb-11-22 07:00AM	Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes (Investor's Business Daily)
Feb-10-22 07:00AM	Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development (GlobeNewswire)
Feb-09-22 07:00AM	Atea Pharmaceuticals to Present at 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Feb-02-22 05:38PM	Vanguard Capital Wealth Advisors Buys VanEck Gold Miners ETF, ViacomCBS Inc, Uber Technologies ... (GuruFocus.com)
01:38PM	Emerald Advisers, Llc Buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals ... (GuruFocus.com)
07:00AM	Atea Pharmaceuticals Announces Publication of Data Supporting Bemnifosbuvirs (AT-527) Novel Mechanism of Action Against SARS-CoV-2 in Nature Communications (GlobeNewswire)
Jan-28-22 05:05AM	With A 4.3% Return On Equity, Is Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) A Quality Stock? (Simply Wall St.) +5.75%
Jan-07-22 07:00AM	Atea Pharmaceuticals Highlights Strategic Priorities for 2022 (GlobeNewswire)

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sommadossi Jean-Pierre	President, CEO, and Chairman	Feb 01 '24	Sale	3.85	56,910	218,819	116,557	Feb 02 09:30 PM
Horga Maria Arantxa	Chief Medical Officer	Feb 01 '24	Sale	3.84	15,870	60,963	25,664	Feb 02 09:29 PM
Corcoran Andrea	See Remarks	Feb 01 '24	Sale	3.84	15,843	60,915	670,208	Feb 02 09:31 PM
Hammond Janet MJ	Chief Development Officer	Feb 01 '24	Sale	3.84	14,029	53,913	35,362	Feb 02 09:24 PM
Foster Wayne	EVP, Chief Accounting Officer	Feb 01 '24	Sale	3.84	12,477	47,904	20,857	Feb 02 09:26 PM
Vavricka John	Chief Commercial Officer	Feb 01 '24	Sale	3.84	11,819	45,420	21,515	Feb 02 09:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVIR

Atea Pharmaceuticals Inc

Upgrade your FINVIZ experience